We use cookies to customise content for your subscription and for analytics.
If you continue to browse Lexology, we will assume that you are happy to receive all our cookies. For further information please read our Cookie Policy.

Search results

Order by: most recent most popular relevance



Results: 1-10 of 78

FDA Releases Series of Gene Therapy Guidance Documents: From Drug Development to Postmarket Monitoring
  • Mintz Levin Cohn Ferris Glovsky and Popeo PC
  • USA
  • July 11 2018

In a highly anticipated step, which had been teased by agency leadership in their public appearances over the past several months, FDA released a


Biosimilars in the Limelight - A Lot Has Happened Since January 2018
  • Mintz Levin Cohn Ferris Glovsky and Popeo PC
  • USA
  • June 20 2018

A lot has happened since we last addressed new biosimilar developments in January 2018. In the intervening months, there have been many significant


FDA Alters Course on Definition of Compounding “Facility” in Final Guidance
  • Mintz Levin Cohn Ferris Glovsky and Popeo PC
  • USA
  • May 14 2018

Businesses engaged in human drug compounding, both traditional pharmacies and the more recently created outsourcing facilities, have been on quite a


NDAANDA Holders Must Affirmatively Submit Data to FDA or Risk Losing Products’ Active Listing in The Orange Book
  • Mintz Levin Cohn Ferris Glovsky and Popeo PC
  • USA
  • January 18 2018

Pharmaceutical industry stakeholders know that drug prices, market competition, supply chain challenges, and shortages of critical drug products have


NDAANDA Holders Must Affirmatively Submit Data to FDA or Risk Losing Products’ Active Listing in The Orange Book
  • Mintz Levin Cohn Ferris Glovsky and Popeo PC
  • USA
  • January 18 2018

Pharmaceutical industry stakeholders know that drug prices, market competition, supply chain challenges, and shortages of critical drug products have


FDA Resets Enforcement Priorities for OTC Homeopathic Drugs
  • Mintz Levin Cohn Ferris Glovsky and Popeo PC
  • USA
  • January 2 2018

Happy New Year! And now on to your regular Consumer Product Matters programming Another Federal agency with a consumer-protection mandate has taken a


FDA 2017 Year In Review: Therapeutic Products Energized by Cures Act, Bold Leadership
  • Mintz Levin Cohn Ferris Glovsky and Popeo PC
  • USA
  • December 18 2017

As is the tradition here at Health Law & Policy Matters, towards the end of the year we take stock of what transpired in our respective industries and


OTC Drug Manufacturers: Keep Your Eyes and Ears on Congress
  • Mintz Levin Cohn Ferris Glovsky and Popeo PC
  • USA
  • October 10 2017

As we previously blogged about in mid-2016, Food and Drug Administration officials have been exploring and pushing for the creation of a new user fee


FDA Takes First Steps to Cut Regulations, Solicits Public Feedback
  • Mintz Levin Cohn Ferris Glovsky and Popeo PC
  • USA
  • September 11 2017

Since our March 17th post about President Trump's executive actions aiming to implement his deregulatory agenda, several important developments


FDA Commissioner Announces Stem Cell Enforcement Shift, Plans to Develop Comprehensive Regenerative Medicine Policies
  • Mintz Levin Cohn Ferris Glovsky and Popeo PC
  • USA
  • September 5 2017

In a major public move that has been long-awaited by proponents of evidence-based stem cell science, FDA Commissioner Scott Gottlieb issued a lengthy